Leerink Partners Lowers Medtronic (NYSE:MDT) Price Target to $104.00

Medtronic (NYSE:MDT) had its price objective lowered by equities researchers at Leerink Partners from $117.00 to $104.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical technology company’s stock. Leerink Partners’ target price would indicate a potential upside of 33.19% from the company’s current price.

Other analysts also recently issued reports about the company. BTIG Research set a $90.00 target price on Medtronic in a research report on Wednesday. Daiwa Securities Group decreased their target price on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Citigroup decreased their target price on Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Piper Sandler decreased their target price on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research report on Wednesday, April 1st. Finally, Barclays lifted their price objective on Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. Sixteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.67.

Medtronic Stock Up 5.9%

Shares of MDT opened at $78.09 on Thursday. The company has a market cap of $100.25 billion, a PE ratio of 21.75, a P/E/G ratio of 1.76 and a beta of 0.58. The business has a fifty day moving average of $81.67 and a 200 day moving average of $92.21. Medtronic has a 52-week low of $73.31 and a 52-week high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. The company had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s revenue was up 9.9% on a year-over-year basis. During the same period last year, the company earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, sell-side analysts expect that Medtronic will post 5.54 EPS for the current year.

Hedge Funds Weigh In On Medtronic

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Medtronic by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after purchasing an additional 1,888,381 shares during the last quarter. State Street Corp grew its stake in Medtronic by 2.0% in the fourth quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after purchasing an additional 1,199,621 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Medtronic by 2.7% in the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock valued at $5,150,420,000 after purchasing an additional 1,419,730 shares during the last quarter. Capital Research Global Investors grew its stake in Medtronic by 12.6% in the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after purchasing an additional 3,880,174 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Medtronic by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock worth $2,665,832,000 after acquiring an additional 231,919 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic topped Q4 expectations with revenue of $9.81 billion and adjusted EPS of $1.55, supported by strong demand in cardiovascular devices and standout growth in Cardiac Ablation Solutions, which jumped 78% globally. Article Title
• Positive Sentiment: Management said FY2026 delivered Medtronic’s strongest annual revenue growth in 10 years, while FY2027 guidance calls for 6.75% to 7.25% organic revenue growth and EPS of $5.90 to $6.00, reinforcing the company’s growth outlook. Article Title
• Positive Sentiment: Medtronic also raised its quarterly dividend to $0.72 per share, a signal of confidence in cash flow and shareholder returns. Article Title
• Positive Sentiment: The company highlighted momentum in its Hugo robotic surgery platform and new strategic investments in cardiac ablation technologies, which could support longer-term growth and product expansion. Article Title
• Neutral Sentiment: Wall Street reacted positively even though some investors remain focused on tariff pressures, margin headwinds, and FY2027 EPS guidance that came in slightly below the consensus estimate. Article Title

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).